Llama y Separa tu Cita!

Fijo: 3169450 - 3127950

Movil: 318 3169450

 

does augmentin treat group b strep

does augmentin treat group b strep

In a single-blind study, 134 patients with bronchopneumonia or lobar pneumonia were randomly assigned to receive 400 mg of loracarbef twice daily or 500/125 mg of amoxicillin/clavulanate three times daily for 10 to 14 days. Treatment efficacy was evaluated in 38 patients treated with loracarbef and in 39 treated with amoxicillin/clavulanate in whom pre-treatment positive cultures of pathogens susceptibile to the study drugs were isolated. Streptococcus pneumoniae and Haemophilus influenzae were cultured as single pathogens in 40.3% of the evaluable patients. Among the evaluable patients, 100% of the loracarbef group and 92.3% of the amoxicillin/clavulanate group had a favorable clinical response (cure or improvement). Bacteriologic response was favorable and the pathogen was eliminated or presumed eliminated in 97.4% of the loracarbef-treated patients and in 92.3% of the amoxicillin/clavulanate-treated patients. Treatment was discontinued in one loracarbef-treated patient because Ludwig's angina, unrelated to the study drug, was diagnosed and in five amoxicillin/clavulanate-treated patients because of diarrhea (two patients), rash (two patients), and nausea and vomiting (one patient). Diarrhea, the most frequently cited adverse event, was reported by 6.1% of the loracarbef-treated patients and 11.8% of the amoxicillin/clavulanate-treated patients. Asthenia was reported by 0% and 8.8% of the loracarbef and amoxicillin/clavulanate patients, respectively. It is concluded that both loracarbef and amoxicillin/clavulanate are safe and effective in the treatment of acute bacterial pneumonia. augmentin zawiesina ulotka.

To compare the efficacy and tolerability of a 3-day course of azithromycin with a 10-day course of amoxicillin/clavulanic acid in the treatment of acute sinusitis in adults. augmentin side effects itching.

In a study lasting over two years the frequency and sensitivity of moraxella catarrhalis causing respiratory tract infections were studied. Sputum samples from patients with lower respiratory tract infections were screened for moraxella catarrhalis. The organisms isolated identified and their sensitivity determined by simple methods which are practicable. The study shows that 22.4% of the infections were due to moraxella catarrhalis and 98% of the isolates were sensitive to amoxicillin-culvanalic acid (augmentin). The paper signifies the importance of reporting moraxella catarrhalis and its treatment. augmentin onset of action.

Nuestras Visitas

Contáctenos

Info: 3169450 - 3127950 - 318 3169450
Dirección: Ciudadela Comercial Unicentro Cali
OASIS - Consultorio y Clínica Of. 307
Cali Colombia
E-mail:
Esta dirección de correo electrónico está siendo protegida contra los robots de spam. Necesita tener JavaScript habilitado para poder verlo.

Donde Estamos

Siguenos en FB